Share Name Share Symbol Market Type
Celgene Corp. NASDAQ:CELG NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -$0.54 -0.57% $93.76 $93.34 $94.50 $94.689 $93.32 $94.67 10,590,794 00:59:57

Bristol-Myers, Celgene Get FTC Request For More Info

26/03/2019 11:57am

Dow Jones News

Historical Stock Chart

1 Month : From Mar 2019 to Apr 2019

Click Here for more Celgene Charts.
   By Colin Kellaher 

Bristol-Myers Squibb Co. (BMY) on Tuesday said the U.S. Federal Trade Commission has requested more information as part of its antitrust review of the company's planned $74 billion acquisition of Celgene Corp. (CELG).

The New York biopharmaceutical company said the so-called "second request" from the FTC involves a review of marketed and pipeline products for the treatment of psoriasis.

Bristol-Myers said the companies plan to work with the FTC to show that the deal won't harm competition.

Bristol-Myers said the FTC's request extends the antitrust waiting period for the deal, but said it still expects to complete the Celgene acquisition in the third quarter.


Write to Colin Kellaher at


(END) Dow Jones Newswires

March 26, 2019 07:42 ET (11:42 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

1 Year Celgene Chart

1 Year Celgene Chart

1 Month Celgene Chart

1 Month Celgene Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20190420 14:42:45